Real-World Use of Trazodone in Older Persons in Long Term Care Setting: A Retrospective Study
- PMID: 39482555
- DOI: 10.1002/gps.70009
Real-World Use of Trazodone in Older Persons in Long Term Care Setting: A Retrospective Study
Abstract
Background: Trazodone, an antidepressant drug is also largely used in several medical contexts. Insomnia, behavioral disorders, and anxiety may be underlying symptoms for prescribing trazodone. This cross-sectional study aims to identify reasons for trazodone prescription, assess the efficacy, as well as identify any related side effects in older persons living in long term care facilities (LTCFs).
Methods: Older adults aged ≥ 60 years, at risk of or affected with Covid-19 and enrolled in the GeroCovid Observational study from LTCFs, and using trazodone were included. A structured questionnaire was administered to treating physicians regarding reasons for trazodone prescription, discontinuation, possible adverse events and benefits.
Results: Thirty-seven out 74 LTCFs participating in both the GeroCovid and GeroCovid Vax studies completed the questionnaire regarding trazodone use. Of the 427 participants included in this study analysis, we found that 43% had diagnoses of dementia and depression, 33% had dementia, no behavioral and psychological symptoms of dementia (BPSD) and no depression, 14% had dementia with BPSD and no depression, and < 11% had only depression. The main reasons for trazodone prescription included agitation, insomnia, depression and anxiety. Trazodone use was reported as partially or totally effective in more than 90% of participants using the drug. Falls were the most frequent adverse event (30% of participants).
Conclusions: Our data suggest that trazodone behaves as an eclectic antidepressant that, in the clinical practice, may also be used for BPSD and insomnia, especially in older people with dementia.
Keywords: BPSD; LTCFs; dementia; depression; older adults; trazodone.
© 2024 John Wiley & Sons Ltd.
References
-
- “Abstracts of the 18th Congress of the European Geriatric Medicine Society: Live From London and Online, 28–30 September 2022,” supplement, European Geriatric Medicine 13, no. 1 (2022): 1–439, Erratum in: Eur Geriatr Med. 2023 Feb 6, https://doi.org/10.1007/s41999‐022‐00711‐8.
-
- A. Iaboni, S. E. Bronskill, K. B. Reynolds, et al., “Changing Pattern of Sedative Use in Older Adults: A Population‐Based Cohort Study,” Drugs & Aging 33, no. 7 (2016): 523–533, https://doi.org/10.1007/s40266‐016‐0380‐3.
-
- D. Macías Saint‐Gerons, C. Huerta Álvarez, P. García, et al., “Trazodone Utilization Among the Elderly in Spain. A Population‐Based Study,” Revista de Psiquiatía y Salud Mental 11 (2018): 208–215, https://doi.org/10.1016/j.rpsm.2016.11.003.
-
- K. Y. Jaffer, T. Chang, B. Vanle, et al., “Trazodone for Insomnia: A Systematic Review,” Innovations in Clinical Neuroscience 14 (2017): 24–34.
-
- A. Cuomo, A. Bianchetti, A. Cagnin, et al., “Trazodone: A Multifunctional Antidepressant. Evaluation of Its Properties and Real‐World Use,” Journal of Gerontology and Geriatrics 69, no. 2 (2021): 120–129, https://doi.org/10.36150/2499‐6564‐N320.